Literature DB >> 3122798

Effect of chronic valproic acid treatment on plasma and urine carnitine levels in children: decreased urinary excretion.

B Melegh1, J Kerner, G Kispál, G Acsádi, M Dani.   

Abstract

Plasma levels and urinary carnitine excretion rates were determined in children treated with valproic acid (n = 11) and in age and sex matched controls (n = 11). Urine was collected throughout two consecutive 24 h periods in both groups, and blood samples were taken on the first day of collection after an overnight fast. The plasma level of total and free carnitine was significantly lower in the treated group (24.3 +/- 2.2 vs 34.9 +/- 2.4 and 16.8 +/- 1.8 vs 26.5 +/- 2.1 nanomol/ml; values are means +/- SEM), while there was no significant alteration in the acylcarnitine fraction. In the treated group of children a significant reduction was found in the plasma beta-hydroxybutyrate level indicating a limited fatty acid utilization (23.2 +/- 2.5 vs 81.9 +/- 7.8 nanomol/ml). Urinary total and free carnitine decreased from 286.4 +/- 57.8 to 120.8 +/- 18.2 and from 154.3 +/- 33.6 to 21.2 +/- 5.8 mumol/day, respectively; the acyled fraction was not significantly reduced. In one child, urinary carnitine excretion was followed during the first ten days of treatment. After the 2nd day a decrease of the total and free fraction was observed, confirming previous data obtained during chronic VPA treatment. It has been concluded that the decreased plasma carnitine associated with chronic VPA treatment is not a result of an increased excretion rate, but more likely the consequence of a relatively insufficient endogenous carnitine synthesis. The decreased plasma BOB level probably due to limited fatty acid utilization might also be a metabolic consequence of depressed carnitine concentration.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3122798

Source DB:  PubMed          Journal:  Acta Paediatr Hung        ISSN: 0231-441X


  7 in total

Review 1.  Drug-Nutrition Interactions and the Brain: It's Not All in Your Head.

Authors:  Joseph I Boullata
Journal:  Curr Nutr Rep       Date:  2019-06

2.  Involvement of recognition and interaction of carnitine transporter in the decrease of L-carnitine concentration induced by pivalic acid and valproic acid.

Authors:  Noboru Okamura; Shuichi Ohnishi; Hiroyuki Shimaoka; Ryo Norikura; Hiroshi Hasegawa
Journal:  Pharm Res       Date:  2006-08       Impact factor: 4.200

3.  Heterozygotes for plasmalemmal carnitine transporter defect are at increased risk for valproic acid-associated impairment of carnitine uptake in cultured human skin fibroblasts.

Authors:  I Tein; S DiMauro; Z W Xie; D C De Vivo
Journal:  J Inherit Metab Dis       Date:  1995       Impact factor: 4.982

Review 4.  Carnitine transport: pathophysiology and metabolism of known molecular defects.

Authors:  I Tein
Journal:  J Inherit Metab Dis       Date:  2003       Impact factor: 4.982

Review 5.  Valproate hepatotoxicity syndrome: hypotheses of pathogenesis.

Authors:  J R Stephens; R H Levy
Journal:  Pharm Weekbl Sci       Date:  1992-06-19

6.  Embryonic Hypotaurine Levels Contribute to Strain-Dependent Susceptibility in Mouse Models of Valproate-Induced Neural Tube Defects.

Authors:  John W Steele; Ying Linda Lin; Nellie Chen; Bogdan J Wlodarczyk; Qiuying Chen; Nabeel Attarwala; Madhu Venkatesalu; Robert M Cabrera; Steven S Gross; Richard H Finnell
Journal:  Front Cell Dev Biol       Date:  2022-02-21

7.  Blood Levels of Ammonia and Carnitine in Patients Treated with Valproic Acid: A Meta-analysis.

Authors:  Saaya Yokoyama; Norio Sugawara; Kazushi Maruo; Norio Yasui-Furukori; Kazutaka Shimoda
Journal:  Clin Psychopharmacol Neurosci       Date:  2022-08-31       Impact factor: 3.731

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.